Logo image of INFI

INFINITY PHARMACEUTICALS INC (INFI) Stock Fundamental Analysis

NASDAQ:INFI - Nasdaq - US45665G3039 - Common Stock - Currency: USD

0.0447  -0.04 (-46.98%)

After market: 0.04 0 (-10.51%)

Fundamental Rating

1

Taking everything into account, INFI scores 1 out of 10 in our fundamental rating. INFI was compared to 559 industry peers in the Biotechnology industry. INFI may be in some trouble as it scores bad on both profitability and health. INFI is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

INFI had negative earnings in the past year.
INFI had a negative operating cash flow in the past year.
In the past 5 years INFI always reported negative net income.
In the past 5 years INFI always reported negative operating cash flow.
INFI Yearly Net Income VS EBIT VS OCF VS FCFINFI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 -50M -100M -150M

1.2 Ratios

INFI has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
INFI Yearly ROA, ROE, ROICINFI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 0 200 -200 -400 -600

1.3 Margins

The Gross Margin of INFI (39.70%) is better than 76.94% of its industry peers.
INFI does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 39.7%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
INFI Yearly Profit, Operating, Gross MarginsINFI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 0 -500 -1K -1.5K -2K

More info and screens

1

2. Health

2.1 Basic Checks

INFI does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for INFI has been increased compared to 1 year ago.
INFI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
INFI Yearly Shares OutstandingINFI Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 20M 40M 60M 80M
INFI Yearly Total Debt VS Total AssetsINFI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M 250M

2.2 Solvency

Based on the Altman-Z score of -63.75, we must say that INFI is in the distress zone and has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -63.75, INFI is doing worse than 98.02% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -63.75
ROIC/WACCN/A
WACC9.35%
INFI Yearly LT Debt VS Equity VS FCFINFI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 0 50M -50M -100M -150M

2.3 Liquidity

INFI has a Current Ratio of 1.65. This is a normal value and indicates that INFI is financially healthy and should not expect problems in meeting its short term obligations.
INFI has a Current ratio of 1.65. This is amonst the worse of the industry: INFI underperforms 83.86% of its industry peers.
INFI has a Quick Ratio of 1.65. This is a normal value and indicates that INFI is financially healthy and should not expect problems in meeting its short term obligations.
INFI has a worse Quick ratio (1.65) than 82.70% of its industry peers.
Industry RankSector Rank
Current Ratio 1.65
Quick Ratio 1.65
INFI Yearly Current Assets VS Current LiabilitesINFI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M 250M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has been growing slightly by 5.66% over the past year.
Looking at the last year, INFI shows a quite strong growth in Revenue. The Revenue has grown by 15.88% in the last year.
Measured over the past years, INFI shows a very negative growth in Revenue. The Revenue has been decreasing by -15.45% on average per year.
EPS 1Y (TTM)5.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%17.61%
Revenue 1Y (TTM)15.88%
Revenue growth 3Y-4.74%
Revenue growth 5Y-15.45%
Sales Q2Q%-15.01%

3.2 Future

INFI is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 12.63% yearly.
The Revenue is expected to grow by 83.41% on average over the next years. This is a very strong growth
EPS Next Y6.16%
EPS Next 2Y-5.92%
EPS Next 3Y12.63%
EPS Next 5YN/A
Revenue Next Year1.89%
Revenue Next 2Y14.92%
Revenue Next 3Y-25.99%
Revenue Next 5Y83.41%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
INFI Yearly Revenue VS EstimatesINFI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2026 2027 2028 2029 2030 50M 100M 150M
INFI Yearly EPS VS EstimatesINFI Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -0.5 -1 -1.5 -2 -2.5

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for INFI. In the last year negative earnings were reported.
Also next year INFI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INFI Price Earnings VS Forward Price EarningsINFI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INFI Per share dataINFI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.1 -0.2 -0.3 -0.4 -0.5

4.3 Compensation for Growth

INFI's earnings are expected to grow with 12.63% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-5.92%
EPS Next 3Y12.63%

More info and screens

0

5. Dividend

5.1 Amount

INFI does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

INFINITY PHARMACEUTICALS INC

NASDAQ:INFI (9/13/2023, 8:17:37 PM)

After market: 0.04 0 (-10.51%)

0.0447

-0.04 (-46.98%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-08 2023-08-08/amc
Earnings (Next)11-13 2023-11-13/amc
Inst Owners0%
Inst Owner Change0%
Ins Owners3.33%
Ins Owner Change0%
Market Cap4.06M
Analysts43.33
Price Target0.31 (593.51%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-12.04%
Min EPS beat(2)-12.04%
Max EPS beat(2)-12.04%
EPS beat(4)0
Avg EPS beat(4)-110.56%
Min EPS beat(4)-223.56%
Max EPS beat(4)-12.04%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)60.27%
Min Revenue beat(2)-18.35%
Max Revenue beat(2)138.89%
Revenue beat(4)1
Avg Revenue beat(4)5.14%
Min Revenue beat(4)-88.72%
Max Revenue beat(4)138.89%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)4%
EPS NY rev (1m)0%
EPS NY rev (3m)5.15%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)100%
Revenue NY rev (1m)0%
Revenue NY rev (3m)100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.58
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.5
EYN/A
EPS(NY)-0.56
Fwd EYN/A
FCF(TTM)-0.43
FCFYN/A
OCF(TTM)-0.43
OCFYN/A
SpS0.03
BVpS-0.41
TBVpS-0.41
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 39.7%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.12
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.65
Quick Ratio 1.65
Altman-Z -63.75
F-Score4
WACC9.35%
ROIC/WACCN/A
Cap/Depr(3y)2%
Cap/Depr(5y)231.2%
Cap/Sales(3y)0.42%
Cap/Sales(5y)15.58%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)5.66%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%17.61%
EPS Next Y6.16%
EPS Next 2Y-5.92%
EPS Next 3Y12.63%
EPS Next 5YN/A
Revenue 1Y (TTM)15.88%
Revenue growth 3Y-4.74%
Revenue growth 5Y-15.45%
Sales Q2Q%-15.01%
Revenue Next Year1.89%
Revenue Next 2Y14.92%
Revenue Next 3Y-25.99%
Revenue Next 5Y83.41%
EBIT growth 1Y9.92%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y1.4%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y1.4%
OCF growth 3YN/A
OCF growth 5YN/A